Melkart

Vildagliptin, the active ingredient in Melkart, is a DPP‑4 inhibitor presented as a pharmaceutical product for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Melkart as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melkart is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus and related therapeutic pathways.

- Type 2 diabetes mellitus: helps lower blood glucose by enhancing insulin secretion in response to meals. - Adjunct to diet and exercise: used together with lifestyle measures to achieve target HbA1c levels. - Combination therapy: can be combined with metformin or other antidiabetic agents when monotherapy is insufficient.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: mild cold‑like symptoms. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes. - Bullous pemphigoid: rare skin blistering disorder. - Acute kidney injury: sudden decline in renal function.

Before initiating therapy, consider the following precautions: - Renal impairment: dose adjustment may be required based on renal function. - Hepatic impairment: use with caution in patients with liver disease. - Elderly patients: monitor closely for hypoglycaemia, especially when used with other glucose‑lowering agents. - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia; dose titration may be needed. - Pregnancy and lactation: safety not established; avoid unless clearly indicated. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Vildagliptin may interact with other medicines. Review the following:

Major Interactions (Avoid): - Insulin or sulfonylureas: combined use can cause severe hypoglycaemia. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase vildagliptin exposure.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce plasma concentrations of vildagliptin. - Digoxin: potential alteration of digoxin levels; monitor therapeutic range. - Thiazide diuretics: may affect glucose control; observe blood glucose regularly.